Skip to content

Improving outcome in subarachnoid hemorrhage with nadroparin

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-511679-14-00
Enrollment
100
Registered
2024-08-08
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

subarachnoid hemorrhage

Brief summary

30-days’ mortality

Detailed description

Delayed cerebral ischemia, Venous thrombo-embolic complications, Intra- and extracranial hemorrhagic complications, Hemorrhage after external CSF drainage, Rate of other SAH-related complications with subdividing into types of complications, Hydrocephalus, Discharge location, Quality of life, Cognitive functioning, Clinical outcome (modified Rankin Score), Rate of (micro)infarctions number and volume at MR imaging at six months, Mortality at six months

Interventions

DRUGNADROPARINE CALCIQUE ASPEN 5 700 UI / 0
DRUG6 mL
DRUGNADROPARINE CALCIQUE ASPEN 2 850 UI / 0
DRUG3 mL

Sponsors

Amsterdam UMC Stichting
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
30-days’ mortality

Secondary

MeasureTime frame
Delayed cerebral ischemia, Venous thrombo-embolic complications, Intra- and extracranial hemorrhagic complications, Hemorrhage after external CSF drainage, Rate of other SAH-related complications with subdividing into types of complications, Hydrocephalus, Discharge location, Quality of life, Cognitive functioning, Clinical outcome (modified Rankin Score), Rate of (micro)infarctions number and volume at MR imaging at six months, Mortality at six months

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026